Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

Inclusion Criteria: * With histologically or cytologically confirmed malignant disease; -. Be scheduled to receive the first course of MEC to be administered on Day 1 * Using reliable contraceptive measures; * negative serum pregnancy test (if potentially child bearing) Exclusion Criteria: * Received investigational drugs within 30 days before the start of study treatment or scheduled to receive a highly or moderately emetogenic chemotherapeutic agent; * Have a clinically unstable seizure disorder with seizure activity requiring anticonvulsant medication; * Have severe renal or hepatic impairment; * Have positive serology test results; * Have a known contraindication to 5-HT3 receptor antagonists; * Treated with commercially available or investigative palonosetron formulation within 2 weeks prior to start of study treatment; * Allergic to palonosetron or any other 5-HT3 antagonist; * Currently a user of any recreational or illicit drugs (including marijuana) or has current evidence of drug or alcohol abuse or dependence as determined by the investigator; * Will be receiving stem cell rescue therapy in conjunction with study related course of emetogenic chemotherapy; * Received or will receive total body irradiation or radiation therapy to the abdomen or pelvis in the week prior to Treatment Day 1 and/or during the diary reporting period.